Successful discontinuation of fluconazole as secondary prophylaxis for cryptococcosis in AIDS patients responding to highly active antiretroviral therapy

International Journal of STD and AIDS

Volumn 13, Issue 10, 2002, Pages 702-705

  Sheng, W H ^a,c   Hung, C C ^b   Chen, M Y ^b   Hsieh, S M ^a   Chang, S C ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c ROYAL SOCIETY OF MEDICINE   (United Kingdom)

Author keywords

AIDS; Antifungal prophylaxis; Cryptococcosis; Cryptococcus neoformans; Highly active antiretroviral therapy

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; VIRUS LOAD;

EID: 0036788061     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646202760326462     Document Type: Article

References (12)

1. Bozzette SA, Larsen R, Chiu J, et al. A controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:580-4
2. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) USPHS/IDSA Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus 2001:1-65
3. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-8
4. Lopez JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after HAART in patients with HIV infection. N Engl J Med 2001;344:159-67
5. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med 2000;342:1085-92
6. Aberg JA, Price RW, Heeren DM, et al. Discontinuation of antifungal therapy for cryptococcosis after immunologic response to antiretroviral therapy [abstract 250]. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000
7. Mussini C, Cossarizza A, Pezzotti P, et al. Discontinuation or continuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with HAART [abstract 546]. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4-8, 2001
8. Martinez E, Garcia-Viejo MA, Marcos MA, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000;14:2615-17
9. Rollot F, Bossai P, Tubiana R, et al. Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy. AIDS 2001;15:1448-9
10. Nwokolo NC, Fisher M, Gazzard BG, Nelson MR. Cessation of secondary prophylaxis in patients with cryptococcosis. AIDS 2001;15:1438-9
11. Van Elden LJ, Walenkamp AM, Lipovsky MM, et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000;14:2787-800
12. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcomes of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001;183:1328-35